

## Summary of status of development and availability of A/Victoria/361/2011 (H3N2)-like candidate vaccine viruses\*

\* Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS).

[National or Regional control authorities approve the composition and formulation of vaccines used in each country](#)

**15 January 2013**

### Candidate vaccine virus

Unless otherwise indicated all candidate vaccine viruses posted on this table have passed two-way haemagglutination inhibition (HI) test.

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
A/Victoria/361/2011	Wild type virus			WHO CCs NIBSC, UK
	IVR – 165	Classical	CSL, Australia	WHO CCs NIBSC, UK
	X-217	Classical	New York Medical College, USA	WHO CCs NYMC, USA NIBSC, UK
	NIB-79	Classical	NIBSC,UK	WHO CCs NIBSC, UK
A/Ohio/2/2012	Wild type virus			WHO CCs
	X-221	Classical	New York Medical College, USA	CDC, USA NYMC, USA
*A/Texas/50/2012	Wild type virus			WHO CCs
	X-223A	Classical	New York Medical College, USA	CDC, USA NYMC, USA

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
<b>*A/Hawaii/22/2012</b>	<b>Wild type virus</b>			<b>WHO CCs</b>
	<b>X-225</b>	<b>Classical</b>	<b>New York Medical College, USA</b>	<b>CDC, USA NYMC, USA</b>

**\*New candidate vaccine virus**

**Institutes contact details for candidate vaccine viruses orders/information:**

CDC: [axk0@cdc.gov](mailto:axk0@cdc.gov) or [xxx1@cdc.gov](mailto:xxx1@cdc.gov)

VIDRL: [whoflu@influenzacentre.org](mailto:whoflu@influenzacentre.org)

NIID: [flu-vaccine@nih.go.jp](mailto:flu-vaccine@nih.go.jp)

NIBSC: [standards@nibsc.hpa.org.uk](mailto:standards@nibsc.hpa.org.uk) or [enquiries@nibsc.hpa.org.uk](mailto:enquiries@nibsc.hpa.org.uk)

CBER/FDA: [rajesh.gupta@fda.hhs.gov](mailto:rajesh.gupta@fda.hhs.gov)

NYMC: [doris\\_bucher@nymc.edu](mailto:doris_bucher@nymc.edu)

**Reference antigens (freeze-dried)**

Parent virus	Starting materials		Ref Ag / Lot #	Unitage (µgHA/mL)	Available from
	CVV	Egg or Cell			
A/Victoria/361/2011	IVR-165	Egg	2012/92B	94	TGA

**Sheep antisera**

Purified HA from		Order/Lot #	Available from
Parent virus	Egg or Cell		
A/Victoria/361/2011	Egg	AS401	TGA

The above-listed potency testing reagents have been developed with support from manufacturers, and calibrated by the Essential Regulatory Laboratories (ERLs) that provide advice to WHO as part of the influenza vaccine virus selection and development process.

**ERLs contact details for reagents orders/information:**

NIBSC: [standards@nibsc.hpa.org.uk](mailto:standards@nibsc.hpa.org.uk)  
TGA: [influenza.reagents@tga.gov.au](mailto:influenza.reagents@tga.gov.au)  
NIID: [sitamura@nih.go.jp](mailto:sitamura@nih.go.jp)  
CBER/FDA: [Rajesh.Gupta@fda.hhs.gov](mailto:Rajesh.Gupta@fda.hhs.gov)

For general enquiries, please contact [gisrs-whohq@who.int](mailto:gisrs-whohq@who.int)

For other candidate vaccine viruses and potency testing reagents, please go to <http://www.who.int/influenza/vaccines/virus/en/>